Concepedia

Daniel E. Salazar

DE

70

Publications

4.6K

Citations

34

H-Index

1982

Active since

Affiliations

Daiichi Sankyo (United States)(Current)

Eli Lilly (United States)

Bristol-Myers Squibb (United States)

Eli Lilly (United Kingdom)

University at Buffalo, State University of New York

Daniel E. Salazar is an author at Daiichi Sankyo (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1982–2021

70

Publications

70

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

John T. Brandt, Sandra Close, Stephen J. Iturria et al. · Journal of Thrombosis and Haemostasis · 2007 · 726 citations

, , +6

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Nazar Farid, Christopher D. Payne, D. S. Small et al. · Clinical Pharmacology & Therapeutics · 2007 · 321 citations

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

David S. Small, Nagy A. Farid, Christopher D. Payne et al. · The Journal of Clinical Pharmacology · 2008 · 315 citations

, , +15

Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass

Daniel E. Salazar, George B. Corcoran · The American Journal of Medicine · 1988 · 250 citations

, , +11

Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers

Suresh Mallikaarjun, Daniel E. Salazar, Steven L. Bramer · The Journal of Clinical Pharmacology · 2004 · 179 citations

Rows per page

1–5 of 70